

Volatile Anesthetics Activate the Human Tandem Pore Domain Baseline K^+ Channel KCNK5

Andrew T. Gray, M.D., Ph.D.,* Byron B. Zhao, Ph.D.,† Christoph H. Kindler, M.D.,‡ Bruce D. Winegar, Ph.D.,§ Matthew J. Mazurek, B.A.,|| Jie Xu, B.A.,† Raymond A. Chavez, Ph.D.,† John R. Forsayeth, Ph.D.,# C. Spencer Yost, M.D.**

Background: Previous studies have identified a volatile anesthetic-induced increase in baseline potassium permeability and concomitant neuronal inhibition. The emerging family of tandem pore domain potassium channels seems to function as baseline potassium channels in vivo. Therefore, we studied the effects of clinically used volatile anesthetics on a recently described member of this family.

Methods: A cDNA clone containing the coding sequence of KCNK5 was isolated from a human brain library. Expression of KCNK5 in the central nervous system was determined by Northern blot analysis and reverse-transcription polymerase chain reaction. Functional expression of the channel was achieved by injection of cRNA into *Xenopus laevis* oocytes.

Results: Expression of KCNK5 was detected in cerebral cortex, medulla, and spinal cord. When heterologously expressed in *Xenopus* oocytes, KCNK5 currents exhibited delayed activation, outward rectification, proton sensitivity, and modulation

by protein kinase C. Clinical concentrations of volatile general anesthetics potentiated KCNK5 currents by 8–30%.

Conclusion: Human KCNK5 is a tandem pore domain potassium channel exhibiting delayed activation and sensitivity to volatile anesthetics and may therefore have a role in suppressing cellular excitability during general anesthesia. (Key words: Background channel; leak current; mammalian; outward rectifier; pH.)

POTASSIUM (K^+) channels have important functions in many tissues. In nonexcitable tissues, K^+ channels modulate the resting membrane potential, K^+ homeostasis, and signal transduction. In excitable tissues, K^+ channels also control action potential initiation, frequency, and duration. At this time the largest mammalian families of cloned K^+ channels are voltage-gated channels (Kv series) and inward rectifiers (Kir series). These channels contain one pore-forming domain within their primary amino acid sequence and form functional ion channels as tetrameric complexes.¹

Recently, K^+ channel subunits with two pore domains in tandem have been cloned.² This structural feature may allow ion channels to form as homodimers with four pore domains lining the ion conduction pathway.³ The basic structure of mammalian tandem pore domain K^+ channels includes four membrane-spanning domains and a relatively large extracellular segment (50–70 amino acids) preceding the first pore region.¹ Although the genome of *Caenorhabditis elegans* contains a large number (≥ 40) of tandem pore domain K^+ channel subunits,⁴ only seven mammalian subunits of this type have been reported.

The functional properties of mammalian tandem pore domain K^+ channels are diverse.⁵ The family includes the weak inward rectifiers TWIK-1 and TWIK-2, the outward rectifier TREK-1, and the open rectifiers TASK-1 and TRAAK (fig. 1A). Open rectification implies that currents satisfy the Goldman-Hodgkin-Katz current equation for an open channel. Although TWIK-1, TWIK-2, TREK-1 and TASK-1 are expressed in many tissues,

* Assistant Professor, Department of Anesthesia and Perioperative Care, University of California, San Francisco, California.

† Research Scientist, Elan Pharmaceuticals, Menlo Park, California.

‡ Visiting Assistant Professor, Department of Anesthesia and Perioperative Care, University of California, San Francisco, California.

§ Assistant Adjunct Professor, Department of Anesthesia and Perioperative Care, University of California, San Francisco, California.

|| Medical Student, Department of Anesthesia and Perioperative Care, University of California, San Francisco, California.

Principal Scientist, Elan Pharmaceuticals, Menlo Park, California.

** Associate Professor, Department of Anesthesia and Perioperative Care, University of California, San Francisco, California.

Received from the Department of Anesthesia and Perioperative Care, University of California, San Francisco, California; and Elan Pharmaceuticals, Menlo Park, California. Submitted for publication May 12, 1999. Accepted for publication February 3, 2000. Supported by grants no. GM57529 (to Dr. Winegar), GM57740 (to Dr. Forsayeth), and GM51372 and GM58149 (to Dr. Yost) from the National Institutes of Health, Bethesda, Maryland. Presented in part at the annual meeting of the American Society of Anesthesiologists, Dallas, Texas, October 11, 1999.

Address reprint requests to Dr. Yost: Department of Anesthesia and Perioperative Care, 513 Parnassus Avenue, Room S-261, Box 0542, San Francisco, California 94143. Address electronic mail to: spyost@itsa.ucsf.edu


A MAMMALIAN VOLATILE ANESTHETIC-ACTIVATED K⁺ CHANNEL

Fig. 1. (A) Predicted membrane topology of KCNK5 and other mammalian tandem pore domain K⁺ channels. Outer (o) and inner (i) sides of the plasma membrane are indicated. (B) Phylogenetic tree of the known members of the mammalian tandem pore domain K⁺ channel family.

TRAAK is exclusively expressed in the central nervous system.⁶ Tandem pore domain K⁺ channels are not gated by physiologic ligands or voltage and therefore serve as baseline (or background) channels.⁷

Physiologic baseline K⁺ channels have been described in a number of mammalian tissues, including pancreas,⁸ corneal endothelia,⁹ sympathetic ganglia,¹⁰ carotid bodies,¹¹ and thin myelinated axons.¹² Electrophysiologic properties of cloned outward and open rectifier baseline K⁺ channels closely resemble baseline K⁺ currents that underlie the resting membrane potential of vertebrate myelinated nerves.^{7,12,13} Thus, these channels likely contribute to the resting membrane conductance of myelinated nerves that limits action potential duration.

Baseline K⁺ channels also may have a role in mediating effects of volatile anesthetics.¹⁴ The concept that volatile anesthetics enhance neuronal K⁺ permeability has received increasing experimental support over the past 20 yr. Hyperpolarization induced by volatile anesthetics has now been described in a wide variety of cortical, hippocampal, and spinal neurons.¹⁵⁻¹⁸ Most recently, Sirois *et al.*¹⁹ found that hypoglossal motor neurons display an increase in K⁺ conductance with application of clinical concentrations of volatile anesthetics. These results indicate that volatile anesthetics can increase K⁺ conductance in neuronal tissue, leading to hyperpolarization and decreased responsiveness to neuronal excitation. Specific volatile anesthetic-activated K⁺ channels were first identified in invertebrate nervous tissue.^{20,21} Recently, Patel *et al.*²² showed that baseline currents passed by the mammalian tandem pore domain K⁺ channels TREK-1 and TASK-1, when expressed in cultured cells, can be activated by volatile anesthetics.

Here we report the functional expression, tissue distribution, and anesthetic activation of another mammalian tandem pore domain K⁺ channel. The cloning of

this K⁺ channel and its basic physiology were previously described.²³ This channel has been named KCNK5 because it is the fifth member of the mammalian tandem pore domain K⁺ channel family isolated (potassium channel subfamily K).

Methods

Isolation of a cDNA Clone

A 360-base pair expressed sequence tag from human prostate epithelium (accession AA533124) was identified with homology to the second pore domain of mammalian tandem pore potassium channels by tBLASTn query.²⁴ These BLAST (Basic Local Alignment Search Tool) queries consisted of protein sequences of previously cloned mammalian tandem pore domain potassium channels used to identify homologous nucleotide sequences of expressed sequence tags. To obtain full-length clones, we screened a human lung cDNA library from Gibco BRL (Gaithersburg, MD) and a human brain cDNA library from Edge Biosystems (Gaithersburg, MD) with modified solution hybridization techniques.²⁵ One full-length clone was found from the BRL library, and multiple clones were found from the Edge library. Both strands of one clone from the Edge library were sequenced and determined to be full length. This clone was therefore chosen for expression studies, and its insert was subcloned into the pOX vector to enhance efficiency of expression in oocytes.²⁶ Sequence analysis and alignments were performed with LaserGene (DNASTAR Inc., Madison, WI) and the ExpASY server (University of Geneva, Geneva, Switzerland) to search the Prosite database.

Northern Blot Analysis and Reverse-Transcription Polymerase Chain Reaction

A 500-base pair restriction fragment was excised from the expressed sequence tag clone (AA533124) by *EcoRI* and *AatII*. This DNA fragment was labeled with the RediPrime DNA labeling system (Amersham, Arlington Heights, IL) and hybridized against commercially available human multiple brain region Northern blots (Clontech, Palo Alto, CA) by standard methods and exposed to x-ray film at -80°C .

To examine KCNK5 expression in the spinal cord and peripheral nervous system, reverse-transcription polymerase chain reaction (RT-PCR) was performed on adult male Sprague-Dawley rat tissues. Messenger RNA was isolated (Micro-FastTrack kit; Invitrogen, Carlsbad, CA) and cDNA synthesized with avian myeloblastosis virus reverse transcriptase (1st Strand cDNA Synthesis kit; Boehringer-Mannheim, Indianapolis, IN). PCR primers based on the human KCNK5 sequence were used²³: 5'-CTGCTCACCTCGGCCATCATCTTC-3' and 5'-GTAGAGGCCCTCGATGTAGTTCCA-3'. PCR conditions were as follows: 30 s at 94°C , 30 s at 55°C , and 90 s at 72°C for 30 cycles. The resultant PCR product was gel-purified and confirmed to be KCNK5 by sequencing. Control reactions were performed under the same PCR conditions with primers for cyclic adenosine monophosphate (AMP) response element-binding protein (CREB): 5'-ACTGTAACTTAGTGCAGCTGCC-3' and 5'-CTGAGTTCGGAGAAA-GTCTT-3'.

Site-directed mutagenesis was performed on the KCNK5 clone with the QuikChange kit according to the instructions of the manufacturer (Stratagene, La Jolla, CA). Nucleotide changes in the mutagenized cDNA were verified by sequencing.

Transcript Preparation and Oocyte Electrophysiology

cRNA transcripts were synthesized from linearized cDNA templates using T3 or T7 RNA polymerases (mMessage mMachine; Ambion, Austin, TX). Defolliculated *Xenopus laevis* oocytes were injected with 1–15 ng cRNA using standard methods for oocyte preparation and maintenance.⁷ One to 4 days after injection, two-electrode voltage clamp recordings were performed at room temperature (GeneClamp 500B; Axon Instruments, Foster City, CA). Most voltage pulse protocols were applied from a holding potential of -80 mV using 1-s voltage pulse steps ranging from -140 to $+40$ mV in 20-mV increments, with 1.5-s interpulse intervals. Except where noted, all two-electrode voltage clamp ex-

periments were performed using frog Ringer's solution (composition: 115 mM NaCl, 2.5 mM KCl, 1.8 mM CaCl_2 , 10 mM HEPES, pH 7.6) or high K^+ frog Ringer's solution (composition: 2.5 mM NaCl, 115 mM KCl, 1.8 mM CaCl_2 , 10 mM HEPES, pH 7.6) as perfusate. Recordings were obtained in a 25- μl recording chamber at flow rates of 1–4 ml/min. Signals were filtered using a four-pole low-pass Bessel filter set at a 50–100 Hz cutoff before sampling at 100–1,000 Hz. Water-injected oocytes were used as controls, undergoing the same treatments as transcript-injected oocytes.

For volatile anesthetic studies, a full-length TRAAK clone⁶ was isolated from a mouse brain cDNA library with PCR (primers 5'-CGAATTCCTGCCTCTGGAAGGACCATGCGCAGC-3' and 5'-GCTCTAGACCTACCCGGCAGGGCCTGTCTCG-3'). The PCR conditions of the first cycle were as follows: 94°C , 30 s; 64°C , 30 s; 72°C , 90 s. The annealing temperature was then decreased 1°C per cycle until it reached 56°C , and PCR was continued for 20 more cycles. The PCR product of expected size was gel-purified and subcloned into the pOX vector at the *EcoRI* and *XbaI* sites. The clone identity was confirmed by sequencing.

Racemic isoflurane (Anaquest, Madison, WI), halothane with 0.01% thymol (wt/wt; Ayerst Laboratories, Inc. Philadelphia, PA and Halocarbon Laboratories, Augusta, SC), and desflurane (Ohmeda, Liberty Corner, NJ) were used for experiments. The nonimmobilizer 1,2-dichlorohexafluorocyclobutane (Lancaster Synthesis Inc., Windham, NH) was also studied.²⁷ Methods for volatile anesthetic delivery and analysis have previously been described.²⁸

Statistical Analysis

Except where noted, data are reported from at least three oocytes. Normalized response is defined as current measured for the -80 to $+40$ mV pulse during the treatment condition relative to the control condition. For quantitation of steady state response, currents were averaged during the last 100 ms of the 1-s voltage pulses. Fractional instantaneous currents were defined as instantaneous currents divided by steady state currents. Mean values are expressed \pm SE with *n* values indicating the number of oocytes studied. Statistical significance is defined by $P < 0.05$.

Results

KCNK5 Sequence

KCNK5 encodes a 499-amino acid protein with a calculated molecular weight of 55.1 kd. Hydrophathy


A MAMMALIAN VOLATILE ANESTHETIC-ACTIVATED K⁺ CHANNEL

Fig. 2. Analysis of KCNK5 distribution. Northern blots of adult human tissues were probed at high stringency with a 500-base pair restriction fragment excised from the expressed sequence tag clone (GenBank accession AA533124). (A) Brain region specific Northern blots. (B) KCNK5 expression in the spinal cord and peripheral nervous system of adult rat tissues. Reverse-transcription polymerase chain reaction products for cortex and medulla, as well as cervical ventral (CV), cervical dorsal (CD), thoracic ventral (TV), thoracic dorsal (TD), lumbar ventral (LV), and lumbar dorsal (LD) spinal cord sections. Lanes for lumbar sympathetic ganglia (LSG) and lumbar dorsal root ganglia (DRG) are also shown. Control reactions showing amplification of cyclic adenosine monophosphate response element-binding protein (CREB) sequence are shown in the same tissues.

analysis predicts that KCNK5, like other mammalian tandem pore domain K⁺ channels, contains four transmembrane domains and two pore loops (fig. 1A). Figure 1B shows the relationship of the KCNK5 sequence to the previous isolated tandem pore domain K⁺ channels based on amino acid homology. KCNK5 has distant protein sequence homology with these other channels (20–24% overall similarity). However, KCNK5 has well-conserved pore and postpore domains, with the highest homology to the other family members found in the second pore region (56% identity).

Tissue Distribution

A human central nervous system Northern blot detected KCNK5 expression in spinal cord (fig. 2A). The band migrated with the 4.4-kb RNA standard. No signal was detected in whole-brain polyA⁺ RNA, although the full-length cDNA was cloned from a human brain cDNA

library. A human multiple tissue Northern blot also showed KCNK5 mRNA expression in several tissues outside the central nervous system, including kidney, liver, pancreas, and placenta.

Figure 2B shows the distribution of KCNK5 expression in the rat central and peripheral nervous systems by RT-PCR. KCNK5 expression was found throughout the spinal cord in both ventral and dorsal sections. In addition, trace levels were detected in cortex, medulla, and lumbar dorsal root ganglia. KCNK5 expression was not observed in lumbar sympathetic ganglia.

Electrophysiology

Xenopus oocytes injected with 1–15 ng of KCNK5 cRNA manifested large (2–25 μ A) outward currents at positive pulse potentials (fig. 3A). In high extracellular K⁺, both inward and outward currents could be observed (figs. 3B and 3C). Unlike previously described mammalian tandem pore domain K⁺ channels, KCNK5 currents did not entirely activate instantaneously; time-dependent gating associated with voltage jumps followed a slow time course ($\tau \approx 150$ ms for -80 to $+40$ -mV pulse in frog Ringer's solution). KCNK5 currents showed no inactivation during voltage pulses as long as 5 s. KCNK5 tail currents were observed after voltage prepulses to 0 mV and reversed near the expected reversal potential for K⁺, implying slow deactivation of potassium currents.

KCNK5 passes little inward current in 2.5 mM extracellular K⁺ (fig. 3C, filled circles), and the current-voltage curves exhibited pronounced outward rectification. In high extracellular K⁺ (fig. 3C, open circles), the zero-current potential shifted with K⁺ equilibrium potential as predicted for a K⁺ selective channel (55 ± 1 mV shift per 10-fold change in extracellular potassium concentration at room temperature).

Pharmacology

KCNK5 currents were reversibly inhibited by extracellular protons in a range relevant to physiologic pH (IC_{50} at approximately pH 7.6; Hill coefficient = 1.1). Proton inhibition was not significantly voltage-dependent. 2,4-Dinitrophenol inhibits oxidative phosphorylation, thereby producing intracellular acidosis. 2,4-Dinitrophenol (1 mM) strongly inhibited KCNK5 currents (normalized response: 0.15 ± 0.01 ; $n = 3$) after 6 min of perfusion (fig. 3D). Another pharmacologic treatment known to lower intracellular pH (5% carbon dioxide in frog Ringer's solution, adjusted to pH 7.6 with bicarbon-




Fig. 3. Biophysical properties of KCNK5 currents in *Xenopus* oocytes studied with two-electrode voltage clamp. (A and B) Whole-cell currents of KCNK5 cRNA-injected oocytes perfused with either frog Ringer's solution (FR) or high-potassium frog Ringer's solution (HK). Voltage pulses (1 s duration) are from -140 to $+40$ mV from a holding potential of -80 mV (inset). (C) Steady state current-voltage curves for FR (filled circles) and HK (open circles). (D) Intracellular pH. Current-voltage curves in the presence or absence of 1 mM 2,4-dinitrophenol.

ate²⁹) also substantially inhibited KCNK5 currents (0.34 ± 0.02 ; $n = 6$).

KCNK5 currents were tested for sensitivity to a number of known pharmacologic modulators of tandem pore domain K^+ channels. Barium (1 mM) inhibition of KCNK5 was strongly voltage-dependent with significant inhibition observed only within the range of potentials from -40 to $+20$ mV (normalized responses, 0.48 ± 0.04 and 0.89 ± 0.02 , respectively; Woodhull $\delta = 0.71$). The divalent cation zinc (100 μ M) produced only slight voltage-dependent inhibition of KCNK5 currents (0.74 ± 0.01 at -20 mV *vs.* 0.81 ± 0.01 at $+40$ -mV pulses; $n = 3$). The antiarrhythmic quinidine (100 μ M) inhibited KCNK5 currents (0.43 ± 0.02 ; $n = 5$) with

similar potency to that reported for the weak inward rectifier TWIK-1.³⁰ Ethanol 17 mM (0.1%) potentiated KCNK5 currents (1.18 ± 0.04 ; $n = 6$).

The protein kinase C activators phorbol-12,13-dibutyrate (500 nM) and phorbol-12-myristate-13-acetate (50 nM) potentiated KCNK5 currents (phorbol-12,13-dibutyrate: 1.81 ± 0.14 , $n = 6$; phorbol-12-myristate-13-acetate: 1.37 ± 0.12 , $n = 3$). The inactive phorbol ester 4- α -phorbol-12,13-dibutyrate (1 μ M) had no effect on KCNK5 currents. Pharmacologic treatments known to increase intracellular cyclic AMP levels and thereby activate protein kinase A (forskolin 10 μ M with 3-isobutyl-1-methylxanthine 1 mM; or 8-bromo-cyclic AMP 300 μ M) had no effect on KCNK5 currents.


A MAMMALIAN VOLATILE ANESTHETIC-ACTIVATED K⁺ CHANNEL

Fig. 4. Volatile anesthetic sensitivity of KCNK5. (A) Whole-cell currents of KCNK5 cRNA-injected oocytes perfused with either frog Ringer's solution (FR) or FR with halothane (270 μM). (B) Concentration-dependence of halothane and isoflurane potentiation of KCNK5 currents as quantified by the normalized response. Four to nine oocytes were studied in each treatment group.

The following pharmacologic treatments had minimal effect ($< 10\%$) on KCNK5 currents: cesium chloride (1 mM), tetraethylammonium (10 mM), magnesium (1 mM), arachidonic acid (10 μM), tetrodotoxin (100 nM), and 4-aminopyridine (1 mM). Clotrimazole (1 μM), which is known to inhibit *Lymnaea* volatile anesthetic-activated potassium currents,³¹ had no effect on KCNK5 currents.

Volatile Anesthetic Sensitivity

Volatile anesthetics potentiated whole cell currents of KCNK5-expressing oocytes (figs. 4A and 4B). This modulation of KCNK5 currents was not significantly voltage-dependent. Application of halothane and isoflurane caused a concentration-dependent increase in KCNK5 currents over a range overlapping the minimum alveolar concentration needed to prevent movement in response to a surgical stimulus in 50% of subjects. Volatile anesthetic (halothane 570 μM) potentiation of inward currents passed by KCNK5 was observed in high-potassium (115 mM) perfusate (-80 mV holding current potentiated $41 \pm 5\%$; $n = 4$). Other volatile anesthetic agents

(desflurane, enflurane, and chloroform), in concentrations that ranged from one to two times the approximate minimum alveolar concentration, also potentiated KCNK5 currents (fig. 5). The volatile nonimmobilizer 1,2-dichlorohexafluorocyclobutane²⁷ slightly inhibited KCNK5 currents at concentrations greater than its minimum alveolar concentration value predicted by the Meyer-Overton hypothesis (normalized response: 0.80 ± 0.02 ; $n = 3$). Isoflurane (500–1,000 μM) did not potentiate the currents of other cloned mammalian tandem pore domain potassium channels expressed in oocytes (normalized responses: 0.86 ± 0.06 , 0.95 ± 0.08 , 0.99 ± 0.02 , and 0.87 ± 0.02 for TWIK-1, TREK-1, TASK-1, and TRAAK, respectively). Volatile anesthetic agents also did not potentiate control currents of water-injected oocytes. The halothane preservative thymol (0.1 μM) had no effect on currents of KCNK5- or water-injected oocytes.

KCNK5 fractional instantaneous currents were not altered by volatile anesthetic treatment. In contrast, treatment of KCNK5-expressing oocytes with extracellular




Fig. 5. Sensitivity of KCNK5 currents to several other volatile anesthetic agents. Concentrations of volatile agents were targeted to values at one to two times the approximate minimum alveolar concentration values.⁴⁷ Data for the anesthetics desflurane (1,160 μM), enflurane (980 μM), halothane (270 μM), and chloroform (1,400 μM) are shown. Four or five oocytes were studied in each treatment group. The 95% confidence intervals of the mean exclude unity for all four treatments.

alkalinity both increased steady state currents and increased fractional instantaneous currents. Chloroform caused hyperpolarization of KCNK5-injected oocytes and had no effect on water-injected oocytes (fig. 6). Halothane (380 and 680 μM) hyperpolarized KCNK5-injected oocytes (3.4 ± 0.4 , $n = 6$; and 4.4 ± 0.5 , $n = 9$; mean \pm SE) and did not hyperpolarize water-injected oocytes. Site-directed mutagenesis was used to introduce termination codons into the C-terminal coding region. KCNK5 C-terminal truncation mutants (at amino acid positions 252 or 278) did not exhibit spontaneous or volatile anesthetic-evoked activity.




Fig. 6. Modulation by chloroform of the resting membrane potential (RMP) of *Xenopus* oocytes injected with either water or KCNK5 cRNA. Data were obtained in frog Ringer's solution under current-clamp 2 days after injection. Six to 13 oocytes were studied in each treatment group.

Discussion

Volatile Anesthetic Activation of KCNK5

Despite more than 150 yr of clinical use, the basic mechanisms underlying volatile anesthetic action are not yet understood. In the current study we have shown that the function of a member of a mammalian ion channel family responsible for baseline K^+ currents (KCNK5) can be enhanced by volatile anesthetics. Previously, we reported that these anesthetic agents potentiate currents from the yeast tandem pore domain K^+ channel TOK1.²⁸ Patel *et al.*⁵² subsequently reported that the archaic volatile anesthetic chloroform potentiated currents through a mammalian tandem pore domain K^+ channel, TREK-1, when expressed in cultured COS cells. The potentiation of KCNK5 currents by volatile anesthetics shown here provides another example of the potentiating effects of volatile anesthetics on members of this family and additional evidence for the hypothesis that volatile anesthetic action may relate to an anesthetic-induced increase in baseline K^+ conductances. Volatile anesthetic modulation of tandem pore domain potassium channels may complement concomitant effects on other ion channels, such as enhancement of inhibitory γ -aminobutyric acid-mediated currents or reduction of excitatory glutamatergic currents.

In our studies, chloroform did potentiate TREK-1 currents in *Xenopus* oocytes. However, we did not observe isoflurane potentiation of currents of several other mammalian tandem pore domain potassium channels (TWIK-1, TREK-1, TASK-1, and TRAAK) when expressed in the same system. This finding contrasts with the recent data of Patel *et al.*,²² who found potentiation of TASK-1 and TREK-1 by clinical volatile anesthetics. The discrepancy between these results may relate to differences in the expression systems (*Xenopus* oocytes *vs.* COS cells), causing different cell-specific modifications or accessory subunit assembly.

Structural determinants of volatile anesthetic modulation of tandem pore domain potassium channels have recently been investigated. The last 48 amino acids of the C-terminus of TREK-1 are essential for volatile anesthetic activation but not for basal activity.²² However, unlike TREK-1, C-terminal truncations of KCNK5 did not result in functional channels. Although this finding suggests different mechanisms of volatile anesthetic activation among mammalian tandem pore domain potassium channels, truncations of KCNK5 could also alter its trafficking and assembly by elimination of consecutive positively charged amino acids in the C-terminus.³³

Recent studies have suggested that volatile anesthetics prevent movement in response to noxious stimuli through their actions at the spinal cord.³⁴⁻³⁶ This action seems separate from the mechanisms that lead to amnesia or unconsciousness.³⁷ Although the molecular site of action within the spinal cord is unclear, volatile anesthetics hyperpolarize both sensory and motor neurons in spinal cord preparations, which suggests the role of an increased baseline potassium conductance.^{15,19,38-41} The highest level of KCNK5 expression in the central nervous system was found in the spinal cord, but KCNK5 could also be detected in cerebral cortex and brainstem tissues by the more sensitive method of RT-PCR. Because KCNK5 expression was observed in dorsal and ventral sections of spinal cord tissue, anesthetic modulation of the channel may have significant effects on both sensory and motor pathways.

Modulation by Protons

KCNK5 currents are highly sensitive to extracellular pH. Some level of tonic proton inhibition is present at physiologic pH, as higher extracellular pH potentiated KCNK5 currents. Extracellular or intracellular acidity from tissue ischemia can depolarize a wide variety of cells.^{42,43} Acid-sensitive baseline K⁺ channels, such as KCNK5, may partly mediate this depolarization. Changes in both intracellular and extracellular pH also can occur with neuronal activity.⁴⁴

Of the previously isolated tandem pore domain K⁺ channels, TOK1, TWIK-1, and TWIK-2 are inhibited by intracellular acidity.^{30,45,46} Inhibition of TOK1 by intracellular acidity has been observed in excised patches, whereas for TWIK-1 this mechanism is thought to be indirect. We observed inhibition of KCNK5 currents after treatment of oocytes with 2,4-dinitrophenol or carbon dioxide, suggesting that KCNK5 is also inhibited by intracellular acidity. However, other consequences of these treatments (e.g., altered intracellular adenosine triphosphate levels, ionized calcium levels, etc.) could also be responsible for this effect.

In summary, we have isolated a human cDNA encoding a tandem pore domain potassium channel that, when heterologously expressed, exhibits sensitivity to volatile anesthetic agents. Among excitable tissues, the expression of this channel is most prominent in spinal cord. The modulation of channel activity by anesthetic agents closely resembles that of physiologic baseline potassium channels; therefore, further studies of cellular localization will help to determine effects of channel modulation on excitability *in vivo*.

The authors thank Nozomi Hyodo for help with the electrophysiologic studies, Douglas Bayliss for mouse TREK-1, Shannan Downey for excellent technical assistance, and Winifred von Ehrenburg for editorial assistance.

References

1. Yost CS: Potassium channels: Basic aspects, functional roles, and medical significance. *ANESTHESIOLOGY* 1999; 90:1186-203
2. Ketchum KA, Joiner WJ, Sellers AJ, Kaczmarek LK, Goldstein SA: A new family of outwardly rectifying potassium channel proteins with two pore domains in tandem. *Nature* 1995; 376:690-5
3. Lesage F, Reyes R, Fink M, Duprat F, Guillemare E, Lazdunski M: Dimerization of TWIK-1 K⁺ channel subunits via a disulfide bridge. *EMBO J* 1996; 15:6400-7
4. Bargmann CI: Neurobiology of the *Caenorhabditis elegans* genome. *Science* 1998; 282:2028-33
5. Goldstein SA, Wang KW, Ilan N, Pausch MH: Sequence and function of the two P domain potassium channels: Implications of an emerging superfamily. *J Mol Med* 1998; 76:13-20
6. Fink M, Lesage F, Duprat F, Heurteaux C, Reyes R, Fosset M, Lazdunski M: A neuronal two P domain K⁺ channels stimulated by arachidonic acid and polyunsaturated fatty acids. *EMBO J* 1998; 17:3297-308
7. Leonoudakis D, Gray AT, Winegar BD, Kindler CH, Harada M, Taylor DM, Chavez RA, Forsayeth JR, Yost CS: An open rectifier potassium channel with two pore domains in tandem cloned from rat cerebellum. *J Neurosci* 1998; 18:868-77
8. Schmid A, Schulz I: Characterization of single potassium channels in mouse pancreatic acinar cells. *J Physiol (Lond)* 1995; 484:661-76
9. Rae JL, Dewey J, Cooper K: Properties of single potassium-selective ionic channels from the apical membrane of rabbit corneal endothelium. *Exp Eye Res* 1989; 49:591-609
10. Koyano K, Tanaka K, Kuba K: A patch-clamp study on the muscarine-sensitive potassium channel in bullfrog sympathetic ganglion cells. *J Physiol (Lond)* 1992; 454:231-46
11. Buckler KJ: A novel oxygen-sensitive potassium current in rat carotid body type I cells. *J Physiol (Lond)* 1997; 498:649-62
12. Baker M, Bostock H, Grafe P, Martius P: Function and distribution of three types of rectifying channel in rat spinal root myelinated axons. *J Physiol (Lond)* 1987; 383:45-67
13. Goldstein SA, Price LA, Rosenthal DN, Pausch MH: ORK1, a potassium-selective leak channel with two pore domains cloned from *Drosophila melanogaster* by expression in *Saccharomyces cerevisiae*. *Proc Natl Acad Sci U S A* 1996; 93:13256-61
14. Franks NP, Lieb WR: Background K⁺ channels: An important target for volatile anesthetics? *Nat Neurosci* 1999; 2:395-6
15. Nicoll RA, Madison DV: General anesthetics hyperpolarize neurons in the vertebrate central nervous system. *Science* 1982; 217:1055-7
16. Berg-Johnsen J, Langmoen IA: Isoflurane hyperpolarizes neurons in rat and human cerebral cortex. *Acta Physiol Scand* 1987; 130:679-85
17. el-Beheiry H, Puil E: Postsynaptic depression induced by isoflurane and Althesin in neocortical neurons. *Exp Brain Res* 1989; 75:361-8
18. Southan AP, Wann KT: Inhalation anaesthetics block accommodation of pyramidal cell discharge in the rat hippocampus. *Br J Anaesth* 1989; 63:581-6

19. Sirois JE, Pancrazio JJ, Lynch CL, Bayliss DA: Multiple ionic mechanisms mediate inhibition of rat motoneurons by inhalation anaesthetics. *J Physiol (Lond)* 1998; 512:851-62
20. Franks NP, Lieb WR: Volatile general anaesthetics activate a novel neuronal K⁺ current. *Nature* 1988; 333:662-4
21. Winegar BD, Owen DF, Yost CS, Forsayeth JR, Mayeri E: Volatile general anaesthetics produce hyperpolarization of *Aplysia* neurons by activation of a discrete population of baseline potassium channels. *ANESTHESIOLOGY* 1996; 85:889-900
22. Patel AJ, Honore E, Lesage F, Fink M, Romey G, Lazdunski M: Inhalational anaesthetics activate two-pore-domain background K⁺ channels. *Nat Neurosci* 1999; 2:422-6
23. Reyes R, Duprat F, Lesage F, Fink M, Salinas M, Farman N, Lazdunski M: Cloning and expression of a novel pH-sensitive two pore domain K⁺ channel from human kidney. *J Biol Chem* 1998; 273:30863-9
24. Altschul SF, Gish W, Miller W, Myers EW, Lipman DJ: Basic local alignment search tool. *J Mol Biol* 1990; 215:403-10
25. Shepard AR, Rae JL: Magnetic bead capture of cDNAs from double-stranded plasmid cDNA libraries. *Nucleic Acids Res* 1997; 25:3183-5
26. Jegla T, Salkoff L: A novel subunit for shal K⁺ channels radically alters activation and inactivation. *J Neurosci* 1997; 17:32-44
27. Koblin DD, Chortkoff BS, Laster MJ, Eger EI 2nd, Halsey MJ, Ionescu P: Polyhalogenated and perfluorinated compounds that disobey the Meyer-Overton hypothesis. *Anesth Analg* 1994; 79:1043-8
28. Gray AT, Leonoudakis DL, Winegar BD, Forsayeth JR, Yost CS: TOK1 is a volatile anaesthetic stimulated K⁺ channel. *ANESTHESIOLOGY* 1998; 88:1076-84
29. Guillemare E, Lazdunski M, Honore E: Glibenclamide opens ATP-sensitive potassium channels in *Xenopus* oocyte follicular cells during metabolic stress. *Mol Pharmacol* 1995; 47:588-94
30. Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G, Barhanin J: TWIK-1, a ubiquitous human weakly inward rectifying K⁺ channel with a novel structure. *EMBO J* 1996; 15:1004-11
31. Lopes CM, Franks NP, Lieb WR: Actions of general anaesthetics and arachidonic pathway inhibitors on K⁺ currents activated by volatile anaesthetics and FMRFamide in molluscan neurones. *Br J Pharmacol* 1998; 125:309-18
32. Patel AJ, Honore E, Maingret F, Lesage F, Fink M, Duprat F, Lazdunski M: A mammalian two pore domain mechano-gated S-like K⁺ channel. *EMBO J* 1998; 17:4283-90
33. Zerangue N, Schwappach B, Jan YN, Jan LY: A new ER trafficking signal regulates the subunit stoichiometry of plasma membrane K_{ATP} channels. *Neuron* 1999; 22:537-48
34. Antognini JF, Schwartz K: Exaggerated anaesthetic requirements in the preferentially anaesthetized brain. *ANESTHESIOLOGY* 1993; 79:1244-9
35. Rampil JJ: Anaesthetic potency is not altered after hypothermic spinal cord transection in rats. *ANESTHESIOLOGY* 1994; 80:606-10
36. Collins JG, Kendig JJ, Mason P: Anaesthetic actions within the spinal cord: Contributions to the state of general anaesthesia. *Trends Neurosci* 1995; 18:549-53
37. Eger EI 2nd, Koblin DD, Harris RA, Kendig JJ, Pohorille A, Halsey MJ, Trudell JR: Hypothesis: Inhaled anaesthetics produce immobility and amnesia by different mechanisms at different sites. *Anesth Analg* 1997; 84:915-8
38. Whitney JF, Glenn LL: Pentobarbital and halothane hyperpolarize cat alpha-motoneurons. *Brain Res* 1986; 381:199-203
39. Takenoshita M, Takahashi T: Mechanisms of halothane action on synaptic transmission in motoneurons of the newborn rat spinal cord in vitro. *Brain Res* 1987; 402:303-10
40. Sugiyama K, Muteki T, Shimoji K: Halothane-induced hyperpolarization and depression of postsynaptic potentials of guinea pig thalamic neurons in vitro. *Brain Res* 1992; 576:97-103
41. Langmoen IA, Larsen M, Berg-Johnsen J: Volatile anaesthetics: Cellular mechanisms of action. *Eur J Anaesthesiol* 1995; 12:51-8
42. Bear CE, Davison JS, Shaffer EA: Intracellular pH influences the resting membrane potential of isolated rat hepatocytes. *Biochim Biophys Acta* 1988; 944:113-20
43. Wilde AA, Aksnes G: Myocardial potassium loss and cell depolarisation in ischaemia and hypoxia. *Cardiovasc Res* 1995; 29:1-15
44. Chesler M, Kaila K: Modulation of pH by neuronal activity. *Trends Neurosci* 1992; 15:396-402
45. Lesage F, Guillemare E, Fink M, Duprat F, Lazdunski M, Romey G, Barhanin J: A pH-sensitive yeast outward rectifier K⁺ channel with two pore domains and novel gating properties. *J Biol Chem* 1996; 271:4183-7
46. Chavez RA, Gray AT, Zhao BB, Kindler CH, Mazurek MJ, Mehta Y, Forsayeth JR, Yost CS: TWIK-2, a new weak inward rectifying member of the tandem pore domain potassium channel family. *J Biol Chem* 1999; 274:7887-92
47. Franks NP, Lieb WR: Molecular and cellular mechanisms of general anaesthesia. *Nature* 1994; 367:607-14